NY judge requires Actavis to keep Namenda IR on market
This article was originally published in Scrip
Executive Summary
Judge Robert Sweet in the US District Court for the Southern District of New York will require Actavis to keep selling Namenda (memantine) immediate-release tablets, derailing the company's plan to discontinue distribution of the twice-daily pills in January before generics hit the market in mid-2015.